Erratum: Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia (European Journal of Clinical Pharmacology 62, (919-926) DOI: 10.1007/s00228-006-0188-x);Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia

European Journal of Clinical Pharmacology

Volumn 62, Issue 11, 2006, Pages 919-926

  Doki, Kosuke ^a   Homma, Masato ^a   Kuga, Keisuke ^a   Kusano, Kazutomi ^b   Watanabe, Shigeyuki ^a   Yamaguchi, Iwao ^a   Kohda, Yukinao ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

CYP2D6 genotype; Flecainide; Intermediate metabolizer; Japanese; Population pharmacokinetics

Indexed keywords

CREATININE; CYTOCHROME P450 2D6; FLECAINIDE;

ADULT; AGED; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA;

EID: 33750439114     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0213-0     Document Type: Erratum

References (28)

1. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, Baroffio R, Gaggioli G (2004) Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 351:2384-2391
2. Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A, Chaves-Gnecco D, Branch RA (2004) Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76:618-627
3. Conard GJ, Cronheim GE, Klempt HW (1982) Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients. Arzneimittelforschung 32:155-159
4. Conard GJ, Ober RE (1984) Metabolism of flecainide. Am J Cardiol 53:41B-51B
5. Crozier IG, Ikram H, Kenealy M, Levy L (1987) Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm. Am J Cardiol 59:607-609
6. Deneer VH, Lie-A-Huen L, Kingma JH, Proost JH, Gossen SA, Stuurman A, Uytdehaag GM, Dunselman PH, Brouwers JR (2004) Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. Eur J Clin Pharmacol 60:693-701
7. Doki K, Homma M, Kuga K, Watanabe S, Yamaguchi I, Kohda Y (2004) Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography. J Pharm Biomed Anal 35:1307-1312
8. Forland SC, Cutler RE, McQuinn RL, Kvam DC, Miller AM, Conard GJ, Parish S (1988) Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. J Clin Pharmacol 28:727-735
9. Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, Azuma J (2000) The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 380:303-308
10. Funck-Brentano C, Becquemont L, Kroemer HK, Buhl K, Knebel NG, Eichelbaum M, Jaillon P (1994) Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 55:256-269
11. Hertrampf R, Gundert-Remy U, Beckmann J, Hoppe U, Elsasser W, Stein H (1991) Elimination of flecainide as a function of urinary flow rate and pH. Eur J Clin Pharmacol 41:61-63
12. Homma M, Kuga K, Doki K, Katori K, Yamaguchi I, Sugibayashi K, Kohda Y (2005) Assessment of serum flecainide trough levels in patients with tachyarrhythmia. J Pharm Pharmacol 57:47-51
13. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, Liao CL, Zhang LM (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198-207
14. Ishiguro A, Kubota T, Soya Y, Sasaki H, Yagyu O, Takarada Y, Iga T (2005) High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction. Anal Biochem 337:256-261
15. Johnston A, Warrington S, Turner P (1985) Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. Br J Clin Pharmacol 20:333-338
16. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I, Brockmoller J (2002) Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101-109
17. Kreeger RW, Hammill SC (1987) New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. Mayo Clin Proc 62:1033-1050
18. Lie-A-Huen L, Proost JH, Kingma JH, Meijer DK (1990) Absorption kinetics of oral and rectal flecainide in healthy subjects. Eur J Clin Pharmacol 38:595-598
19. McQuinn RL, Pentikainen PJ, Chang SF, Conard GJ (1988) Pharmacokinetics of flecainide in patients with cirrhosis of the liver. Clin Pharmacol Ther 44:566-572
20. Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M (1989) The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 45:562-567
21. Muhiddin KA, Johnston A, Turner P (1984) The influence of urinary pH on flecainide excretion and its serum pharmacokinetics. Br J Clin Pharmacol 17:447-451
22. Salerno DM, Granrud G, Sharkey P, Krejci J, Larson T, Erlien D, Berry D, Hodges M (1986) Pharmacodynamics and side effects of flecainide acetate. Clin Pharmacol Ther 40:101-107
23. Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, Katada J, Hashimoto M, Matsui H, Taki K, Kaminuma T, Yamamoto M, Aida Y, Ohashi A, Ozawa N (2003) Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 18:48-70
24. Spivack C, Gottlieb S, Miura DS, Somberg JC (1984) Flecainide toxicity. Am J Cardiol 53:329-330
25. Takada M, Goto T, Kotake T, Saito M, Kawato N, Nakai M, Gunji T, Shibakawa M (2005) Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring. J Clin Pharm Ther 30:5-12
26. Tanaka E (1999) Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24:339-346
27. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570-575
28. Winkelmann BR, Leinberger H (1987) Life-threatening flecainide toxicity. A pharmacodynamic approach. Ann Intern Med 106:807-814